Nature provides us with countless chemicals that can improve our lives. Trees and plants often supply them, but in such small amounts that they’re hard to extract, leading to waste and environmental degradation. To harness natural chemicals more effectively, synthetic biology first attempted to rewire living cells to make them easier to extract. But cells are complicated and not easily rewired. Invizyne’s new approach, SimplePath streamlines synthetic biology by removing cells altogether, along with their complexities. Using our proprietary, sustainable enzyme systems we can build simple, efficient reactors for chemical production.
| Website | https://www.invizyne.com/ |
| Revenue | $6.6 million |
| Employees | 32 (19 on RocketReach) |
| Founded | 2014 |
| Industry | Biotechnology |
| Keywords | Biorefinery, Biochemicals, Biotechnology, Drug Discovery, Natural Chemicals, Agricultural Chemicals, Plant Extracts, Fine Chemicals, Chemical Extraction, Sustainable Chemistry, Green Chemistry, Renewable Resources, Chemical Engineering, Process Optimization, Environmental Sustainability, Waste Reduction, Resource Efficiency, Botanical Extracts |
| Competitors | BASF, Evonik, DuPont, Corteva Agriscience, Novozymes, Zymergen, Inc., Amyris, Codexis, Inc., Geno +39 more (view full list) |
Looking for a particular Invizyne employee's phone or email?
The Invizyne annual revenue was $6.6 million in 2026.
Gary Schuman is the CFO of Invizyne.
19 people are employed at Invizyne.
Invizyne is based in Monrovia, California.